Search
for
Sort by
Research
360-390 / 1000+ resultsresearch Flurandrenolide
research Evaluation of efficacy of derma roller sizes vs topical application for administration of QR678 Neo® hair regrowth formulation in the treatment of androgenetic alopecia
research Microneedles in Improving Skin Appearance and Enhanced Delivery of Cosmeceuticals
Microneedle technology is effective for skin rejuvenation and enhancing cosmeceutical delivery, with ongoing innovation and increasing commercialization.
research Alert to US physicians: DHEA, widely used as an OTC androgen supplement, may exacerbate COVID-19
The over-the-counter supplement DHEA could make COVID-19 worse, especially in diabetics and people with G6PD deficiency.
research Dacomitinib-Induced Paronychia Associated With PRIDE Syndrome in a Patient With Non-Small Cell Lung Cancer
Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.
research Use of dermatoscopy and videodermatoscopy in therapeutic follow-up: a review
Dermatoscopy and videodermatoscopy are useful and reliable for tracking treatment progress in various skin conditions.
research SRD5A2 and emerging therapies in androgen-driven disorders
research Carbon‐dioxide laser‐associated PDT treatment of folliculitis decalvans
CO2 laser-associated PDT effectively treated therapy-resistant folliculitis decalvans.
research Intralesional vitamin D3 versus intralesional triamcinolone acetonoid in patchy alopecia areata: a comparative clinical and dermoscopic study
Intralesional vitamin D3 is an effective and safe treatment for patchy alopecia areata with fewer side effects.
research P.08: Development of dissolving microneedles containing finasteride with improved permeability and bioavailability.
Dissolving microneedles with finasteride improve drug delivery for hair loss treatment.
research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
research A Randomized, Multicenter, Evaluator-blind Study to Evaluate the Safety and Effectiveness of VYC-12L Treatment for Skin Quality Improvements
VYC-12L effectively improves skin smoothness, reduces fine lines, and boosts hydration.
research Telecommunication in the COVID-19 era: As an assessment tool for patients with dermatomyositis
Remote monitoring of chronic diseases like dermatomyositis is challenging and needs better tools for early detection and patient education.
research Post SARS-CoV-2 vaccination effluvium
research Short-term efficacy and safety of valproate sustained-release formulation in newly diagnosed partial epilepsy VIPe-study. A multicenter observational open-label study.
Valproate sustained-release is effective and generally safe for short-term treatment of new partial epilepsy.
research Straight hair associated with interferon-alfa plus ribavirin in hepatitis C infection
ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
research The Dermatology Life Quality Index (DLQI ) used as the benchmark in validation of 101 quality‐of‐life instruments: A systematic review
The DLQI is a key tool for measuring quality of life in dermatology.
research Get the essential small equipment you need fast!
Buy the basic tools you need quickly.
research New Instrumentation for Hair Transplantation Surgery
New instruments were introduced to make hair transplantation surgery more precise and improve graft survival.
research Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata
Farudodstat may help prevent hair loss in alopecia areata by stopping immune attacks on hair follicles.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 is generally safe for treating alopecia areata.
research DRUG NEWS
The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
research Responsive Microneedles as a New Platform for Precision Immunotherapy
Microneedles can precisely deliver cancer treatments with fewer side effects.
research Fabrication of polyvinyl pyrrolidone-K90/Eudragit RL100-based dissolving microneedle patches loaded with alpha-arbutin and resveratrol for skin depigmentation
Microneedle patches with alpha-arbutin and resveratrol can effectively reduce skin pigmentation without irritation.
research Polymer conjugated retinoids for controlled transdermal delivery
A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with less inflammation.
research 62339 Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
research Template for Skin Regeneration
The dermal regeneration template is effective in skin regeneration, reducing scarring, and has potential for future improvements.
research A Preliminary Study on Application of Vibrating Device Instead of Topical Anaesthetic Gel During Injection of Local Anaesthesia
Topical anaesthesia reduces injection pain better than a vibrating device.
research Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
Dabrafenib can cause skin growths and sometimes low-grade skin cancer.